6fzr: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6fzr is ON HOLD  until Paper Publication
+==Crystal structure of scFv-SM3 in complex with compound 2==
+<StructureSection load='6fzr' size='340' side='right' caption='[[6fzr]], [[Resolution|resolution]] 1.80&Aring;' scene=''>
-Authors: Bermejo, I.A., Usabiaga, I., Companon, I., Castro-Lopez, J., Insausti, A., Fernandez, J.A., Avenoza, A., Busto, J.H., Jimenez-Barbero, J., Asensio, J.L., Jimenez-Oses, G., Peregrina, J.M., Hurtado-Guerrero, R., Cocinero, E.J., Corzana, F.
+== Structural highlights ==
+<table><tr><td colspan='2'>[[6fzr]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FZR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FZR FirstGlance]. <br>
-Description: Crystal structure of scFv-SM3 in complex with compound 2
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EEQ:2-fluoranyl-~{N}-[(2~{S},3~{R},4~{R},5~{R},6~{R})-6-(hydroxymethyl)-2,4,5-tris(oxidanyl)oxan-3-yl]ethanamide'>EEQ</scene></td></tr>
-[[Category: Unreleased Structures]]
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fzr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fzr OCA], [http://pdbe.org/6fzr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fzr RCSB], [http://www.ebi.ac.uk/pdbsum/6fzr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fzr ProSAT]</span></td></tr>
+</table>
+== Disease ==
+[[http://www.uniprot.org/uniprot/MUC1_HUMAN MUC1_HUMAN]] Note=MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence (PubMed:20816948). Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes.
+== Function ==
+[[http://www.uniprot.org/uniprot/MUC1_HUMAN MUC1_HUMAN]] The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.<ref>PMID:9139698</ref> <ref>PMID:11877440</ref> <ref>PMID:14688481</ref> <ref>PMID:15710329</ref> <ref>PMID:16288032</ref> <ref>PMID:15513966</ref> <ref>PMID:17524503</ref> <ref>PMID:17308127</ref> <ref>PMID:16983337</ref>   The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.<ref>PMID:9139698</ref> <ref>PMID:11877440</ref> <ref>PMID:14688481</ref> <ref>PMID:15710329</ref> <ref>PMID:16288032</ref> <ref>PMID:15513966</ref> <ref>PMID:17524503</ref> <ref>PMID:17308127</ref> <ref>PMID:16983337</ref>
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Asensio, J L]]
+[[Category: Avenoza, A]]
+[[Category: Bermejo, I A]]
+[[Category: Busto, J H]]
 [[Category: Castro-Lopez, J]]
-[[Category: Fernandez, J.A]]
+[[Category: Cocinero, E J]]
-[[Category: Peregrina, J.M]]
+[[Category: Companon, I]]
-[[Category: Asensio, J.L]]
+[[Category: Corzana, F]]
-[[Category: Jimenez-Barbero, J]]
+[[Category: Fernandez, J A]]
-[[Category: Avenoza, A]]
-[[Category: Cocinero, E.J]]
 [[Category: Hurtado-Guerrero, R]]
 [[Category: Insausti, A]]
+[[Category: Jimenez-Barbero, J]]
+[[Category: Jimenez-Oses, G]]
+[[Category: Peregrina, J M]]
 [[Category: Usabiaga, I]]
-[[Category: Jimenez-Oses, G]]
+[[Category: Immune system]]
-[[Category: Bermejo, I.A]]
-[[Category: Busto, J.H]]
-[[Category: Corzana, F]]
-[[Category: Companon, I]]